SST and neuroendocrine neoplasm: Over the course of the last two decades, the imaging and treatment of patients with neuroendocrine neoplasms (NEN) have been redefined with the successful introduction of radiolabelled somatostatin analogues targeting overexpressed somatostatin receptors (SST), especially the somatostatin subtype 2 receptor (SST2) [1,2].